Filtered library · Theme
binary-catalyst-biotech theme · 3 dossiers
Dossiers in the binary-catalyst-biotech theme cluster — 3 names moving on shared catalysts.
All dossiersELVN
Enliven Therapeutics, Inc.
De-risking BCR::ABL1 story: ELVN-001 Phase 1 ENABLE update hits an EHA oral June 11 (T-4) plus webcast 69% cumulative MMR (60/120mg) and 52% in asciminib-pretreated CML, no MTD, $462.6M cash into 1H-2029, Phase 3 ENABLE-2 launching…
TSHA
Taysha Gene Therapies, Inc.
Rett gene therapy narrative re-rated from clinical binary to BLA execution: FDA aligned on a single-arm pivotal with potential BLA off the REVEAL six-month interim, cash funded into 2028 kills the dilution overhang, and Part A shows 100%…
SLS
SELLAS Life Sciences Group, Inc.
Pre-binary retail run-up: SLS ran ~5x off the $1.39 low into an imminent, event-driven Phase 3 REGAL overall-survival readout (78/80 death events as of May 11, 2026). A coin-flip near 52-week highs ($8.23) with parabolic RSI lottery gamma…